Spots Global Cancer Trial Database for Neo-MASCT Immunotherapy for Advanced NSCLC.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neo-MASCT Immunotherapy for Advanced NSCLC.
Official Title: A Phase I/Ⅱ Open, Single Center, One-armed Trail, Neo - MASCT Treatment for Advanced NSCLC of the Safety and Efficacy.
Study ID: NCT03205930
Conditions
Interventions
Study Description
Brief Summary: Neoantigen （Neo）is a new targets for immune cells，that the DC neoantigen immunotherapy was more effective in triggering specific T-cell responses. Neo-MASCT using the DC vaccine and neoantigen T cells .Dendritic cells(DC) was induced from autologous peripheral blood，and be loaded with antigens and re-infused. In vitro, antigen-pulsed DC can stimulate autologous T-cell proliferation and induction of autologous specific cytotoxic T-cells(CTL)，similarly re-infused. The study is aimed to evaluate the safety of Neo-MASCT in patients with advanced NSCLC.
Detailed Description: This study is divided into two stages. The first stage is the safety study in small samples, and the second stage is the sample size expansion phase. 20 failed standard treatment patients with advanced or recurrent NSCLC will be recruited .
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Xiaodong Jiang, Jiangsu, Doctor, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
